Curated news and analysis on clinical trials, drug approvals, and medical research.
Drug enforcement actions in several states led to seizures of meth, heroin, cocaine, and firearms. A Fort Worth man received a 40-year prison sentence, six men were charged in Nassau County, and a corrections officer was arrested.
Eli Lilly's Retevmo met the primary endpoint in a Phase III lung cancer trial, Merck discontinued its TROP2 ADC MK-6837, and a Tango/Revolution combination showed benefit in pancreatic cancer.
4D Molecular Therapeutics (Nasdaq: FDMT) granted a total of 229,700 restricted stock units to 20 new non-executive hires across three awards in 2026 under its Employment Inducement Award Plan. The grants occurred on February 10, April 14, and July 14, as part of Nasdaq-compliant inducement awards.
State Street's top five performing ETFs from June 16 to July 16, 2026, were all in the healthcare sector, with the SPDR S&P Pharmaceuticals ETF (XPH) leading at 11.69%. Other top performers included biotechnology, healthcare services, insurance, and healthcare equipment ETFs.
A securities class action lawsuit alleges REGENXBIO misled investors about the safety of its gene therapy RGX-111. Following an FDA clinical hold due to a patient tumor, the stock fell 17.8% in one day. Affected shareholders have until April 14, 2026 to seek lead plaintiff status.
New CAR T-cell data show 100% MRD negativity in high-risk smoldering multiple myeloma, a novel CAR T approach for AML, and a new T-cell pathway, while a case report warns of a rare therapy-related complication.
High-resolution CT scans, virtual surgical planning, and 3D-printed custom guides are improving precision in pediatric orthopedic surgeries. The approach shortens operative times, reduces radiation exposure, and enhances limb alignment, as shown in a case of a severe tibial deformity. The technology is poised to become standard for complex pediatric procedures.
The FDA approved six cancer therapies in Q2 2026, including first-line sacituzumab govitecan for triple-negative breast cancer and capivasertib for PTEN-deficient prostate cancer. A separate study shows 69% of accelerated-approval cancer drugs need safety updates within 4 years.
Aptar Pharma published three patent applications for GLP-1 inhaled/nasal delivery and launched a system-level injectable development framework. Preclinical data showed up to 10x higher semaglutide Cmax.
Ensitrelvir cut symptomatic COVID-19 after household exposure from 9% to 3% in a trial; Japan approved it for post-exposure use. A redesigned hepatitis C drug, ML2006a4, shows activity against resistant variants.
The global personalized medicine market is projected to grow from $789.39 billion in 2026 to $1.4 trillion by 2035, driven by genomic sequencing and companion diagnostics. North America leads with 46% of implementation, and AI-assisted interpretation is increasingly integrated.
Eli Lilly's Taltz-Zepbound combination achieved significant improvements in two Phase 3b trials for plaque psoriasis and psoriatic arthritis with obesity. Combo therapy led to complete skin clearance and weight loss in psoriasis, and rapid disease activity reduction in psoriatic arthritis. The results were presented at AAD 2026.
The FDA accepted Camurus' NDA resubmission for Oclaiz in acromegaly, setting a December 2026 PDUFA date. The filing follows a June 2026 Complete Response Letter related to third-party manufacturing, with no safety or efficacy issues. Oclaiz is a once-monthly subcutaneous octreotide already approved in the EU as Oczyesa.
New imaging reveals that most flu infections fail due to transcription errors, while host-targeted antivirals aim to bypass resistance by interfering with cellular machinery. The findings from Cell Systems point to new ways to predict viral threats and develop broad-spectrum drugs.
Laboratory monkey prices in China have surged to as much as 180,000 yuan, exceeding average wages, as booming drug research drives demand beyond limited supply. Researchers report that colonies are fully pre-booked, forcing some studies to halt. Supply-demand imbalance is forecast to persist, leading to further price increases.
A clinical study explores whether echocardiography can detect heart amyloid as an early sign of Alzheimer’s, while laboratory research maps a biphasic gene expression cascade in the brain that identifies new therapeutic targets.
Data presented at EHA show that sickle cell disease patients have high interest in gene therapy, with 71% eager to learn more, despite limited awareness and concerns about safety and cost. Early clinical data from approved CRISPR-based therapies demonstrate significant reductions in vaso-occlusive crises and hospital admissions.
RCB Faridabad announces three openings: a ₹1.30L/month Post Doc EIR fellowship, a Project Associate II for TB research, and an apprenticeship for life sciences graduates. Deadlines: Feb 25, Jun 8-9, Jul 24, 2026.
Biotech education expands with new Auburn grad programs, a 2+2 transfer pathway at Elizabethtown/Harford, a USDA K-12 plant biotech initiative at BTI, and a new lab at Baku Engineering University.
Johnson & Johnson is preparing a potential sale of its DePuy Synthes orthopedics unit, valued at over $20 billion, with private equity firms showing interest. Concurrently, the unit has acquired spine implant maker Expanding Innovations to bolster its technology portfolio.
